Skip navigation
BelSU DSpace logo

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-30 of 35 (Search time: 0.017 seconds).
Item hits:
Issue DateTitleAuthor(s)
2016New approaches of morfofunktional pharmacological correction of violations of cardiovascular system in experimental preeclampsiaGureev, V. V.
2015The study of osteoprotective properties of nanoparticulated forms of resveratrol and losartanKoklina, N. Y.; Gudyrev, O. S.; Faitelson, A. V.
2015Use of selective inhibitors of arginase 2 and tadalafil in combined compensation of homocysteine-induced endothelial dysfunctionKoklin, I. S.
2015Concomitant use of statins and s-(2-boron-ethyl)-l-cysteine arginase inhibitor to correct endotoxin-induced endothelial dysfunctionDenisiuk, T. A.; Demchenko, S. A.; Saroyan, K. V.
2017Lipid distress-syndrome and prospects of its correction by statinesDenisiuk, T. A.; Lazareva, G. A.; Provotorov, V. Y.
2020Correction of morphofunctional disorders of the cardiovascular system with asialized erythropoietin and arginase II selective inhibitors KUD 974 and KUD 259 in experimental preeclampsiaLokteva, T. I.; Rozhkov, I. S.; Gureev, V. V.; Gureeva, A. V.; Zatolokina, M. A.
2017Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathologyRagulina, V. A.; Kostina, D. A.; Dovgan, A. P.; Burda, Y. E.; Nadezhdin, S. V.
2020Role of Arginase 2 as a potential pharmacological target for the creation of new drugs to correct cardiovascular diseasesDemchenko, S. A.; Koklin, I. S.; Koklina, N. Y.
2017Pharmacological efficacy of an inhibitor of arginase-2 KUD975 with L-NAME-induced endothelial dysfunctionKudryavtsev, K. V.; Korokin, M. V.; Gudyrev, O. S.
2015Study of the microcirculation level in bone with osteoporosis and osteoporotic fractures during therapy with recombinant erythropoietin, rosuvastatin and their combinationsRajkumar, D. S. R.; Gudyrev, O. S.; Faitelson, A. V.; Pokrovskii, M. V.